暂无数据
产品名称
起订量
单价(含增值税)
库存(PCS)
起订数量
产品简介
| 实际分子量 | 37kDa |
| 英文名称 | Anti-TICAM2 Polyclonal Antibody |
| 靶标 | TICAM2 |
| 别名 | Putative NF-kappa-B-activating protein 502; TCAM2_HUMAN; TICAM-2; TICAM2; TIR containing adapter molecule 2; TIR domain containing adaptor protein; TIR domain-containing adapter molecule 2; TIRAP 3; TIRAP3; TIRAP3a short form; TIRP; Toll-like receptor adaptor protein 3; Toll/interleukin-1 receptor domain-containing protein; TRAM; TRIF-related adapter molecule; |
| 宿主 | Rabbit |
| 预测交叉反应 | Bovine |
| 稀释比例 | WB 1:1000-3000. IHC 1:100-300. |
| Gene ID | 353376/100302736 |
| 保存 | Store at -20°C. Avoid freeze / thaw cycles. |
| Swiss Prot | Q86XR7 |
| 蛋白分子量 | 27/46kDa |
| 储存液 | Buffer: PBS with 0.03% Proclin300, 50% glycerol, pH7.3. |
| 亚细胞定位 | Cytoplasm Cell membrane |
| 免疫原 | Recombinant protein of human TICAM2 |
| 亚型 | IgG |
| 纯化方法 | Affinity purification |
| 背景资料 | Functions as sorting adapter in different signaling pathways to facilitate downstream signaling leading to type I interferon induction (PubMed:16603631, PubMed:16757566, PubMed:25385819, PubMed:25825441)In TLR4 signaling, physically bridges TLR4 and TICAM1 and functionally transmits signal to TICAM1 in early endosomes after endocytosis of TLR4. In TLR2 signaling, physically bridges TLR2 and MYD88 and is required for the TLR2-dependent movement of MYD88 to endosomes following ligand engagement (PubMed:25385819).Involved in IL-18 signaling and is proposed to function as a sorting adapter for MYD88 in IL-18 signaling during adaptive immune response (PubMed:22685567).Forms a complex with RAB11FIP2 that is recruited to the phagosomes to promote the activation of the actin-regulatory GTPases RAC1 and CDC42 and subsequent phagocytosis of Gram-negative bacteria (PubMed:30883606). |
| Public Immunogen Range | 1-236aa |
| 克隆类型 | Polyclonal Antibody |
| 交叉反应 | Human;Mouse |
| 应用 | WB IHC |
| 规格 | 50ul100ul |
注意：
1.本产品仅供科研使用。请勿用于医药、临床诊断或治疗，食品及化妆品等用途。请勿存放于普通住宅区。
2.为了您的安全和健康，请穿好实验服并佩戴一次性手套和口罩操作。
暂无数据
我要询价
*联系方式：
(可以是QQ、MSN、电子邮箱、电话等，您的联系方式不会被公开)
*内容：
